Hemispherix` Ampligen aktivstes Therapeutikum gegen SARS - 500 Beiträge pro Seite

[mpuibs]

Business Wire:
"SARS: Newly NIH Sponsored Studies of Potential Therapies for SARS Now Finds Hemispherx` Ampligen among the Most Active from a Large Pool of 70 -Seventy- Drug Candidates"

Den vollen Wortlaut der Meldung findet ihr unter

http://biz.yahoo.com/bw/030521/215483_1.html


Und ich wollte gerade verkaufen. Konnte Order in letzter Sekunde löschen. An der AMEX geht grad die Post ab.

[skipper2002]

interessiert wohl niemanden

[diddelmax]

#1
ich bleib auch erstmal drin !!!!!!!!!!!!

[sukashi]

Hemispherx
kündigt an,
den Prozess zu beschleunigung, um in Ansicht des von Bundesagenturen berichteten gesteigerten Auftretens von HPV
erwarteter- Alferon N- höherer Produktforderung herzustellen.



Philadelphia, PA, Mittwoch, 21. Mai 2003: Hemispherx Biopharma, Inc. (AMEX: HEB) kündigte heute an, dass es einzelne Produktionsschritte in der Herstellung seiner Führungszusammensetzung, Alferon N beschleunigt hat, um die Erfüllung von erwarteten Bestellungen zu errichten.
Diese Entscheidungen sind gebraucht worden, um den sich ändernden Zielen von Technologiebeschleunigung, Herstellungsagilität, Ausrüstungsproduktivitätszielen und Zeit zu entsprechen.
"Wir sind erfreut, den Punkt des vollen Einblicks in wichtige Faktoren erreicht zu haben, um die Herstellung zu beeinflussen, die uns ermöglichte, den Prozess zu beschleunigen
und dieErreichung der Zunahmenproduktivität und Kostenrentabilität fördern sollte,"
sagte Dr. William A. Carter, Vorstandsvorsitzenden von Hemispherx.


Als Teil eines Erwerbs von den Vermögenswerten von Interferon Wissenschaften, angekündigt am 12. März 2003, erhielt Hemispherx eine FDA genehmigte Produktionseinrichtung über 36.000 m2.
. Das Medikamenteninventar hat einen Wert von mehr als $ 7 Millionen, basierend auf seinem Handelswert, um einen Großhandel mit Kunden zu betreiben, Staat und Bundesagenturen und Medicare einschließend. Für historische Zwecke sind die Großhandelserwerbskosten $ 137,84 für 5 Millionen iu/ml mit einem Durchschnittsgroßhandelspreis von $ 165,41 gewesen. Der Gesamtvermögenswert der Gesellschaft nahm 45% in Folge des Erwerbs von bestimmten Vermögenswerten von Interferon Wissenschaften zu mit für das Halten von Zwecken, des Inventars für entsprechend vom finanziellen Buchführungsnormenbrett gesetzten Standards geschätzt.

Über HPV-
ist der Markt für sexuell übertragene Krankheiten in der Healthcare- Industrie
im Jahr $ 16 Milliarden wert. Es sind bald 20 Millionen mit dem HPV Virus in den Vereinigten Staaten infizierte Leute. Diese Zahlen sind von gemeldeten Fällen, aber man kann davon ausgehen,daß die Dunkelziffer wegen nicht angezeigter Fällen noch weit höher ist.
Dieses Jahr nur infizierten sich5,5 Millionen Leute in den USA an der HPV Infektion, und die Anzahl von Vorfällen wächst weiter dramatisch.

Über Alferon N
ist Alferon N (Interferon alfa n3, abgeleiteter menschlicher Leukozyt) eine hoch gereinigte, natürliche Quelle, glycosylated, multispecies Alphainterferon Produkt, der aus acht Formen des hohen gereinigten Alphas interferon zusammengesetzt ist. Es ist die einzige natürliche Quelle, multispecies Alphainterferon, verkauft gegenwärtig in den USA sowie in bestimmten anderen Ländern, Hongkong (Republik von China) und Singapur einschließend.


Über Hemispherx

Hemispherx Biopharma, ist eine biopharmaceutical Gesellschaft mit der Herstellung und klinischer Entwicklung von neuen Medikamentenentitäten für Behandlung von Virus- und immun basierten chronischen Störungen beschäftigt? Seine Flaggschiffprodukte schließen Alferon und das experimentelle immunotherapeutics ein/antivirals Ampligen und Oragens. Diese neuartige Eiweiße, die für eine Kategorie von Infektion genehmigt sind, und experimentelle Nukleinsäuren werden für global wichtige chronische Viruskrankheiten und Störungen vom immunen System einschließlich HPVs, dem immunen HIV, dem immunen CFS und der immunen Hepatitis entwickelt. Seine Technologie schließt große und kleine Agentenbestandteile für potentielle Behandlung von verschiedenen chronischen Virusinfektionen ein.
Hemispherx hat etwa 400 Patente, die sein Inneres umfassen in intellektuellem Eigenschaftsbesitz, ein vollständig kommerzialisiertes Produkt (Alferon N) und GMP bestätigten Fertigungseinrichtungen für seine neuartigen Pharma Produkte.

gruss
sukashi

[UH1d]

In dieser Sache dürfte auch Interferon interssant werden!
Symbol ifsce.ob, kein gepushe, halte keine dieser Aktie!
http://biz.yahoo.com/bw/030312/125386_1.html
Grüße

[user911]

ich pers. setze derzeit auf "zadaxin" von sciclone pharma WKN 886644 ...ist in vielen Ländern bereits zugelassen für hepatitis b und c und in vielen anderen ländern in der erpronungsphase III ... in china seit kurzem auch gegen sars im Einsatz ... schaut mal selbst ...

http://www.sciclone.com

[Geheimnisvoller]

http://quotes.nasdaq.com/asp/summaryquote.asp?symbol=EDSN%60…

SARS: Newly NIH Sponsored Studies of Potential Therapies for SARS Now Finds Hemispherx` Ampligen among the Most Active from a Large Pool of 70 -Seventy- Drug Candidates

Das wird den Kurs in den nächsten Wochen ankurbeln lassen, denn zu den Fakten kommt die Phantasie der Marktteilnehmer und SARS mutiert leicht und ist in Taiwan ein ungeklärtes Problem.

Geht unter "Summary Quote" auf Company Research-Stock Consultant und ihre werdet die Ankündigung des Bullischen sehen. Heute geht es wieder aufwärts.

Kauf bei 2,00 ist ideal (meine Meinung!!!)

[schwarzu]

Was ist das für eine Scheiß Aktie. Mittlerweile ist sie, trotz wie es schien positiver Nachrichten, um ca. 40% gefallen! Wie könnt ihr da noch positive Aspekte sehen? Sollen alle, die in USA und bei uns zu niedrigen Preisen und fallenden Kursen verkaufen, falsche Infos haben? Dafür gibt es Gründe, auch wenn ich sie leider nicht kenne! Alles andere ist Pusherei! Werde meine Aktien verkaufen und so einen Mist nicht mehr anfassen! Hoffe Ihr seid früher wie ich eingestiegen und könnt Euch wenigstens noch über ein wenig Gewinn erfreuen!

[Geheimnisvoller]

Vor dem Verkaufen folgendes nochmals lesen.
Würde mit dem Verkaufen daher eher noch warten
Persönlicher Tipp. Eher dazukaufen und den Verlust mindern, um schneller wieder im Plus zu sein.


Results for HEB Very Mild Outperform, short term (1-6 wks)
Friday, 23 May 2003, 11:22 am EST (15-20 min delayed) Full Consult on HEB Hemispherx Biopharma Inc
AMEX

Analysis updated hourly starting at 11am EST

Scale: 0 - Neutral, 10 - Extreme

PRICE 2.17, -0.05 pts (-2.2%), Friday, 23 May 2003, 11:22 am EST (15-20 min delayed)
-2, flat from yesterday`s close.
Typical price range from yesterday`s close : ± 0.15 pts, ± 6.7%

VOLUME 95.4k shares traded, average daily volume of 185k shares over the past month.
+114% compared to the typical volume (44.6k)
by Friday, 23 May 2003, 11:22 am EST (15-20 min delayed).


Indicator Summary Summary Help, A summary of bullish and bearish indicators.

_________________

BULLISH Probability - Intermediate trend bullish, uptrend.
Probability - Short term typical pullback, pullback may start to slow.
Confirmation - at support !!!!!!!!!!!!!!!!!!!!!!!!!!!!!
_________________

BEARISH Probability - Mild bearish 3 day chart pattern with Extreme distribution.
Probability - Strong Up trend (1 month), may start to turn sideways!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!


OVERALL 2 bullish probability and 1 bullish confirmation indicators!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
2 bearish probability and 0 bearish confirmation indicators!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!


OVERALL RATING 3, Very Mild Outperform, short term (1-6 wks)

65%, Bullish 35%, Bearish !!!!!!!!!!!!!!!!!!!!!!!!


Position Indicators Positioning Help, Indicators for positioning trade entry and exits.


1 DAY PRICE CHANGE -2, flat (-0.05, -2.2%) from yesterdays close.

SHORT TERM DIRECTION -7, typical pullback, pullback may start to slow.

RALLIES/PULLBACKS Typical: 1.06 pts(48.8%) occurs 25% of the time.
At current stock price Extreme: 1.38 pts(63.6%) occurs 5% of the time.

OVERBOUGHT/SOLD 2, Neutral, odds equally favor long and short trades!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

1 MONTH TREND 7, Strong Up trend, may start to turn sideways.

INTERMEDIATE TREND 10, bullish,
Past 4 months uptrend.

RESISTANCE/SUPPORT 2.17, at support, 2.16 ± 0.14, type double, strength 10
Resistance/Support Help Resistance Above : +13.8% at 2.47 ± 0.17, type triple, strength 10
Support Below : -8.8% at 1.98 ± 0.13, type triple, strength 9


Timing Indicators Timing Help, Indicators for timing trade entry and exits.

CHART ALERT -5, Mild bearish 3 day chart pattern.
-10, Extreme distribution, occurs 10% of the time.

MONEYFLOW 3, Not significant Neutral 1 day moneyflow at this price level

BREAKOUT None!!!!!!!!!!!!!!!!!!!!!!!!!!!

BREAKDOWN None!!!!!!!!!!!!!!!!!!!!!!!!!!


Resistance & Support Areas Resistance/Support Help, Over the past 6 months.


CURRENT PRICE 2.17, at support, 2.16 ± 0.14, type double, strength 10

RESISTANCE ABOVE +13.8% at 2.47 ± 0.17, type triple, strength 10
+35.9% at 2.95 ± 0.2, type single, strength 1
Searched to 4.58 (+111%) over last 6 months.

SUPPORT BELOW -8.8% at 1.98 ± 0.13, type triple, strength 9
-24.4% at 1.64 ± 0.11, type triple, strength 10
-36.4% at 1.38 ± 0.09, type single, strength 8
Searched to 0 (-100%) over last 6 months.


Upside Trade Upside Trade Help, Trade indicators for long trades.


TARGET 1 Price: 2.95 Profit: 35.9%
Stop Limit/Trailing Stop Limit: 1.92 Loss: 11.5%
Profit/Loss Ratio: 3.1 : 1 - Good

TARGET 1 POTENTIAL Fair, there are 1 resistance areas on the way to Target 1

TARGET 1 RESISTANCE +13.8% at 2.47 ± 0.17, type triple, strength 10
+35.9% at 2.95 is Target 1

TARGET 2 Price: 2.95 Profit: 35.9% , for an extreme rally.

BREAKOUT None.


Downside Trade Downside Trade Help, Trade indicators for short trades.


TARGET 1 Price: 1.38 Profit: 36.4%
Cover Limit/Trailing Cover Limit: 2.73 Loss: 25.8%
Profit/Loss Ratio: 1.4 : 1 - Poor

TARGET 1 POTENTIAL Poor, there are 3 support areas on the way to Target 1

TARGET 1 SUPPORT Current price at support: 2.16 ± 0.14, type double, strength 10
-8.8% at 1.98 ± 0.13, type triple, strength 9
-24.4% at 1.64 ± 0.11, type triple, strength 10
-36.4% at 1.38 is Target 1

TARGET 2 Price: 1.07 Profit: 50.7% , for an extreme pullback.

BREAKDOWN None.

[Geheimnisvoller]

HEMISPHERX BIOPHARMA INC - American Stock Exchange: HEB
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time Day Volume
2.18 0.04 (1.80) 2.16 (50) 2.18 (1) 11:56 131,000

Es wird langsam mehr gekauft als verkauft!!!!!!!!

[sukashi]

grobe übersetzung von posting
#9
Resultiert für HEB:
sanfte Outperform, kurze Aussicht- (1-6 wks)

Freitag, 23 Mai2003, 11:22 a.m. EST volle Beratung auf HEB Hemispherx Biopharma Inc
AMEX


Typische Preisspanne von dem gestrigen Ende: ± 0,15 pts, ± 6,7%

Volumen 95,4 k verteilt ,
durchschnittliches tägliches Volumen von 185 k verteilt über den letzten Monat.
+114% verglich mit dem typischen Volumen (44,6 k)
bis Freitag, 23 Mai2003, 11:22 a.m. EST


_________________

BULLISHE Wahrscheinlichkeit
- Mitteltrend bullish, Aufwärtstrend.

Bestätigung an Unterstützung !
_________________

BEARISH Wahrscheinlichkeit
- - sanftes bearish 3 Tagesdiagrammmuster mit äußerster Verteilung.


Allgemeine 2 bullish Wahrscheinlichkeit und 1 bullish Bestätigung Indikatoren .
2 bearish Wahrscheinlichkeit und 0 bearish Bestätigungsindikatoren


65%, Bullish
-
- 35% Bearish !







Mitteltrend , bullish .

Widerstand/Unterstützung 2,17

gruss
sukashi

[greyhound_cc]

SCHAUT EUCH DEN SHORT INTEREST AN....

DA WIRD GEDRÜCKT.....da das Ding sonst explodiert!

Die Meldungen sind grundsätzlich positiv--->>>

Kommt erst die Meldung aus Thailand oder Singapur...wird sie steigen...und erst bei 10 USD halt machen...

[greyhound_cc]

SARS: Newly NIH Sponsored Studies of Potential Therapies for SARS Now Finds Hemispherx` Ampligen among the Most Active from a Large Pool of 70 -Seventy- Drug Candidates
Wednesday May 21, 12:12 pm ET


PHILADELPHIA--(BUSINESS WIRE)--May 21, 2003--Hemispherx Biopharma, Inc. (AMEX: HEB - News) announced today that the Institute for Antiviral Research, sponsored by the National Institutes of Health (NIAID, Virology Branch, Contract No. 1-AI-85348) have just reported a comprehensive new study which screened many test compounds for potential therapy against SARS.
The results of the study entitled "Potential therapies for SARS: Inhibitors of Human Coronavirus Strain OC43 by Antiviral Agents" have identified Ampligen®, a flagship investigational immunotherapeutic of the Company, as having unusually high and consistent antiviral activity against human coronavirus.

About the Assay Method

Human coronavirus (strain OC43) in different amounts was grown in African green monkey kidney cells and thereafter potential antiviral therapies ("the test compounds") were added. Each of the approximately 70 new drug candidates for SARS were introduced to determine levels of possible reduction in virus growth (called "virus yield reduction assay"). Thereafter, these drugs were ranked by their relative ability to inhibit virus and for their ability to protect the target cells from death or severe damage.

About the Compounds Screened for Inhibiting Human Coronavirus

A. "Traditional" Antivirals

An unusual broad array of candidates was selected including many new drugs, submitted by various drug manufacturers, to NIH for screening (18 cpds), also many nucleoside analogues (21 cpds) known to be potentially active against HBV, HIV, herpes, etc.; marketed (FDA approved) antivirals, including ribavirin (for RSV, respiratory syncytal virus) and related compounds (5 cpds); formycin analogs and polyoxometalates and dendrimers and 5 non carbocyclic adenosine analogues (totaling 11 new cpds); new apoptosis inhibitors and new cyclin-dependent kinase inhibitors (6 cpds) as well as adenosine kinase inhibitors (3 cpds); plus miscellaneous phospolipase, attachment / penetration and bunga virus inhibitors, plus cyclohexamide and a coumadin analog (totaling 7 cpds). In total, these compounds represent multiple mechanisms of action designed to stop the human coronavirus at virtually every step of its multiplication within cells.

B. Immune Modulators and Interferons

Human Interferon gamma (recombinant) from Interimmune Corp. and Interferon - alpha consensus (recombinant, Intergen) from Amgen Corp. were also evaluated both alone and in combination. Both are FDA approved products widely used for the treatment of chronic granulomatous disease of lungs and hepatitis C, respectively. Ampligen®, an experimental immunotherapeutic in Phase 3 clinical testing, was provided by the Company under a research collaboration agreement with the NIH. A structurally related compound, termed PolyIC:LC, developed by the NIH scientists and widely available in the Republic of China as a potential broad-spectrum antiviral, was also tested.

About the Results

As compared to all therapeutic products tested, Ampligen ranked with the highest antiviral activity.

Ampligen® was the most consistently active compound tested in the various assay methods used. A structurally related dsRNA compound, poly IC:LC, presently available in China, was not demonstrated to have any significant activity against human coronavirus.

Similarly, ribavirin, which has been widely reported in the media to have been used in the SARS epidemic in Asia (alone or in combination with steroids), was also devoid of significant viral inhibitory activity.

In contrast, Ampligen® demonstrated very high potency at low concentrations (0.4 micrograms per milliliter) and had a favorable safety profile (the ratio of concentration to damage normal cells relative to that necessary to stop viral growth). Only 1 compound, termed iodotubercidin, demonstrated similar potency, however, the results with this compound were very inconsistent within the multiple assay systems of viral inhibition, suggesting that it may provide unpredictable antiviral benefits, in contrast to Ampligen®.

Relative Potency within the Immune Modulator Class: Ampligen(R)
surpassed Recombinant IFN

Both recombinant interferons given alone, provided less antiviral protection than Ampligen (greater than 50%) with the trademarked Intergen (Amgen Corp., originally selected for its high potency) providing only 28% protection and interferon gamma, trademarked Actimune, providing only 18% protection. In fact, to achieve antiviral protection against human coronavirus similar to Ampligen® alone, it was necessary to combine these two different recombinant IFNs, thereby achieving 52% antiviral protection. Except as occurs in the natural antiviral cocktail of alpha interferon, termed Alferon and owned by Hemispherx, the combination of two or more IFNs (recombinant) has been generally deemed too potentially toxic to justify human exposure.

About Hemispherx

Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based chronic disorders. Its flagship products include Alferon and the experimental immunotherapeutics/antivirals Ampligen and Oragens. These novel proteins, approved for a category of STD infection, and experimental nucleic acids are being developed for globally important chronic viral diseases and disorders of the immune system including HPV, HIV, CFS and Hepatitis. Its platform technology includes large and small agent components for potential treatment of various chronic viral infections. Hemispherx has approximately 400 patents comprising its core intellectual property estate, a fully commercialized product (Alferon N) and GMP certified manufacturing facilities for its novel pharma products. For more information please visit www.hemispherx.net

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company`s filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the company (including Ampligen® and Oragens(TM)) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company`s judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon® do not imply that the product will ever be specifically approved commercially for these other treatment indications. The Alferon® asset for overseas sales for a category of STD is currently being acquired by the Company as part of a multi-step purchase contract of inventory, intellectual property, commercial licenses and GMP approved facilities, which house the biological operations.



--------------------------------------------------------------------------------
Contact:
Hemispherx Biopharma, Inc.
Dianne Will, 518/398-6222
[e-mail]
www.hemispherx.net

[ToeJam]

Hemispherx Filed Patent Applications to Combat SARS
Tuesday May 27, 8:34 am ET
Hemispherx Confirms Filing Patent Applications for the Use of Alferon N Injection(R) and Ampligen(R) for treating SARS

PHILADELPHIA--(BUSINESS WIRE)--May 27, 2003-- Hemispherx Biopharma, Inc. (AMEX: HEB - News) announced today that it filed patent applications covering the use of both of its lead compounds, Alferon N Injection® and Ampligen® for the potential treatment and prevention of severe acute respiratory syndrome (SARS).

ADVERTISEMENT
Independent studies have identified Alferon N, a natural source, multispecies alpha interferon product, and Ampligen®, an experimental, double stranded RNA drug acting potentially as an immunomodulator and antiviral, as first candidates for potentially treating SARS. The patent applications that have been filed provide procedures for combating the effects of coronavirus-induced conditions by the administration of Alferon N Injection® or Ampligen® or in combination therapy.

The Company believes it has filed its patent applications in a timely matter with respect to its Alferon and Ampligen technologies, protecting its intellectual property and enhancing shareholder value. The patent procedure has also been mentioned in the press release of May 13, 2003, before any other company released potentially competitive patent applications. Hemispherx has a large knowledge and expertise in the procedures of filing patents and has built up, with close to 400 patents, potentially one of the largest patent portfolio in the biotech industry. Due to the acquisition of the Alferon technology, the Company has further enlarged its world wide patent estate with respect to Alferon N Injection®, including several process patents related to the manufacturing of natural alpha interferon.

About the treatment mechanism

Individuals with chronic diseases or the aged, both conditions associated with weakened cell immunity, are at great risk to accelerated death from SARS. The "spike protein" of coronaviruses further damages the body`s immune apparatus, thus facilitating an increase in virus multiplication. The natural immune "cascade" triggered by the patented compounds may modulate these critical deficiencies in host defense.

About Ampligen®

Ampligen® is an experimental, double stranded RNA drug acting potentially as an immunomodulator and antiviral. Based on in vitro studies, Ampligen® is believed to stimulate the immune system as well as destroy viruses directly. The product is currently in Phase 3 clinical trials for the potential treatment of Chronic Fatigue Syndrome (CFS) and in two Phase 2b clinical trials for the potential treatment of HIV/AIDS. SARS, which is believed to be a coronavirus and the HIV virus, both belong to the group of ribose nucleic acid (RNA) viruses which frequently change and mutate. On May 21, 2003 the Company announced the promising data on a NIH sponsored study on SARS finding Ampligen® having unusually high and consistent antiviral activity against human coronavirus. The study found Ampligen® among the most active drug candidates, compared to approximately 70 others.

About Alferon N

Alferon N (Interferon alfa-n3, human leukocyte derived) is a highly purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high purified alpha interferon. It is the only natural-source, multispecies alpha interferon currently sold in the U.S. for the treatment of a specific indication of STD (refractory condylomata acuminata) and is also approved for sale in certain other countries, including Hong Kong (Peoples Republic of China) and Singapore. On May 19, 2003 the Company reported positive data from an independent study evaluating the effect of Alferon N in the treatment of pig coronavirus (animal model of SARS). The clinical study showed substantial greater survival rates of treated piglets compared with the control group, receiving placebo. Since human SARS apparently has its roots in animal coronavirus, the Company believes that the drug`s effect in the animal study may be relevant to potential human applicability.

About Hemispherx

Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based chronic disorders. Its flagship products include Alferon and the experimental immunotherapeutics/antivirals Ampligen and Oragens. These novel proteins, approved for a category of STD infection, and experimental nucleic acids are being developed for globally important chronic viral diseases and disorders of the immune system including HPV, HIV, CFS and Hepatitis. Its platform technology includes large and small agent components for potential treatment of various chronic viral infections. Hemispherx has approximately 400 patents comprising its core intellectual property estate, a fully commercialized product (Alferon N) and GMP certified manufacturing facilities for its novel pharma products. For more information please visit www.hemispherx.net

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company`s filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the company (including Ampligen® and Oragens(TM)) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company`s judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon® do not imply that the product will ever be specifically approved commercially for these other treatment indications. The Alferon® asset for overseas sales for a category of STD is currently being acquired by the Company as part of a multi-step purchase contract of inventory, intellectual property, commercial licenses and GMP approved facilities, which house the biological operations.
Contact:

Hemispherx Biopharma, Inc.
Investor Relations
Dianne Will, 518/398-6222
[e-mail]
www.hemispherx.net

[Geheimnisvoller]

An #8 von schwarzu

Hoffe Du bist meinem Rat gefolgt.
Diese tollen News werden den Titel in den nächsten Tagen und Wochen steigen lassen.

[schwarzu]

Hi Geheimnisvoller,

ich habe in der Tat nicht verkauft auch wenn mir das sehr schwer gefallen ist. Nachkaufen war aber auch nicht angesagt, da ich bereits ein großes Paket von HEB besitze und nicht vor hatte da noch mehr rein zu buttern! Pharma Titel oder auch Exoten Werte können in der Tat schnell steigen, aber auch sehr schnell wieder fallen. Ich habe in der Vergangenheit bereits negative Erfahrungen mit Pharma Titeln gemacht, da dann irgendwann die Zulassung für ein wichtiges Produkt versagt blieb und die Phantasie aus der Aktie raus war! Ich kann nur hoffen, das HEB weiter fleissig Nachrichten raus bringt, die zumindest aufzeigen, daß da was passiert.

Grüsse,
schwarzu

P.S.: Aufmerksam wurde ich auf den Titel über einen Artikel hier im Wallstreet-online vom 14.05.2003 (ein gewisser Dipl.Betriebswirt S.Heckle, der wohl für GLOBAL BIOTECH INVESTING schreibt). Demzufolge existiert da wohl eine Kaufstudie mit Kurszielen bis USD 25. Selbst bei Kursanstiegen in Bereiche von 8-12 USD (was er dem Titel in den nächsten Monaten zutraut) ist das Potential sicherlich interessant. Aber sehr spekulativ und vor allem müssen weitere positive Nachrichten folgen, sonst versinkt diese Aktie wieder für einen längeren Zeitraum im Nichts!

[Geheimnisvoller]

Hier ist die neueste gute News!!!

___________________________________________________________

Hemispherx Biopharma Announces Independent Study That Shows Ampligen Superior to Other Antivirals Prof. Neyts receives prestigious Prusoff Award for research potentially applicable to SARS


PHILADELPHIA, Jun 23, 2003 (BUSINESS WIRE) -- Hemispherx Biopharma, Inc. (AMEX:
HEB) announced today that the Antiviral Research Group led by Professor Johan
Neyts of the Rega Institute, KUL, Leuven, Belgium has just reported a new study
which screened several immune-based compounds for potential activity against
Coxsackie virus, a human pathogenic agent. The study identifies Ampligen(R), an
important flagship investigational immunotherapeutic, as being superior to other
antivirals, including PolyIC, recombinant interferon and pegelated interferon.
Professor Johan Neyts received this year`s prestigious Prusoff Young
Investigator Lecture Award, based on his outstanding work in antiviral research.

About the Study

The data may be directly applicable to humans since Coxsackie can cause
myocarditis in humans. The Coxsackie virus causes a fulminant myocarditis
(inflammation of heart muscle) in mice within 6 days of infection (Horowitz et
al Nature Medicine, 2000). Ampligen(R) was far superior to other antivirals,
such as interferon (IFN), a special new potent form of IFN termed PEG-IFN and
PolyIC. The experimental compound Ampligen(R) decreased inflamed foci by
approximately 98% and was 10 times superior to recombinant IFN and 15 times to
PEG-IFN. Viral concentrations in heart were decreased more than 99% by
Ampligen(R) and serial EKGs evidenced much improved cardiac performance by
Ampligen(R) treatment. The proportions of myocarditis foci (inflammations) per
heart, expressed as a percentage were: IFN 2.22%, PEG-IFN 3.39%, PolyIC 0.73%
and Ampligen(R) 0.22%. The mock (placebo-control) animals had 10%.

No contracts, grants, financial compensation or other means of indirect support
were provided to the research team or to the academic institution.

About the William Prusoff Young Investigator Lecture Award

The Bristol-Myers Squibb Company (BMS) has endowed the William Prusoff Young
Investigator Lecture Award, which is awarded annually by the International
Society for Antiviral Research (ISAR). The Society`s membership is over 700 and
represents the Who`s Who of scientists involved in antiviral research. ISAR is
an international recognized organization for scientists, involved in antiviral
research and offers a forum for the exchange of scientific information. The
contributions of William H. Prusoff, Ph.D., Professor Emeritus and Senior
Research Scientist in Pharmacology, Yale University, to the development of
antivirals and their clinical use are legendary. Annually the award is given to
one outstanding young scientist, from among 700 potential candidates, who has
demonstrated dedication and excellence in the field of antiviral research and
future potential for contribution to the field and the society.

About the Study and SARS

The present study utilizes a different virus, myocarditis virus, to determine if
protection of critical internal organs in animals (mice) is possible with
Ampligen(R). SARS is now believed to be a multi-system disease according to
recent publications in Lancet, an internationally recognized medical journal.
According to the Asian based clinical researchers, SARS damages many internal
organs (liver, spleen) by attacking and destroying them as it progresses to a
terminal pulmonary phase. The present study suggests that Ampligen(R) may be
able to protect various vital organs, including heart and potential viscera
protection, thereby providing a potential broad-spectrum anti viral defense
mechanism that may enable a multi-organ protection.

About the Company`s SARS programs

Hemispherx has in development several programs to potentially combat SARS with
the use of its lead compounds Alferon N Injection(R), a natural source,
multispecies alpha interferon product, and Ampligen(R), a double stranded RNA
experimental product acting potentially as an immunomodulator and antiviral. The
programs cover procedures for combating the effects of coronavirus-induced
conditions by the administration of Alferon N Injection(R) or the experimental
compound Ampligen(R) or in combination therapy. The Company releases updates on
these programs from time to time. Only clinical testing under well-controlled
conditions can determine efficacy and safety on any entity including Alferon N
Injection(R) and Ampligen(R) in SARS.

About Hemispherx

Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company
engaged in the manufacture and clinical development of new drug entities for
treatment of viral and immune-based chronic disorders. Its flagship products
include Alferon and the experimental immunotherapeutics / antivirals Ampligen
and Oragens. These novel proteins, approved for a category of STD infection, and
experimental nucleic acids are being developed for globally important chronic
viral diseases and disorders of the immune system including HPV, HIV, CFS and
Hepatitis. Its platform technology includes large and small agent components for
potential treatment of various chronic viral infections. Hemispherx has
approximately 400 patents comprising its core intellectual property estate, a
fully commercialized product (Alferon N) and GMP certified manufacturing
facilities for its novel pharma products. The Company plans global clinical
trials in the SARS disease arena where it has a proprietary position and the
disease represents a major potential threat to human welfare. For more
information please visit www.hemispherx.net

Information contained in this news release other than historical information,
should be considered forward-looking and is subject to various risk factors and
uncertainties. For instance, the strategies and operations of Hemispherx involve
risk of competition, changing market conditions, change in laws and regulations
affecting these industries and numerous other factors discussed in this release
and in the Company`s filings with the Securities and Exchange Commission. Any
specifically referenced investigational drugs and associated technologies of the
company (including Ampligen(R) and Oragens(TM)) are experimental in nature and
as such are not designated safe and effective by a regulatory authority for
general use and are legally available only through clinical trials with the
referenced disorders. The forward-looking statements represent the Company`s
judgment as of the date of this release. The Company disclaims, however, any
intent or obligation to update these forward-looking statements. Clinical trials
for other potential indications of the approved biologic Alferon(R) do not imply
that the product will ever be specifically approved commercially for these other
treatment indications including SARS. The Alferon(R) asset for overseas sales
for a category of STD is currently being acquired by the Company as part of a
multi-step purchase contract of inventory, intellectual property, commercial
licenses and GMP approved facilities, which house the biological operations.

SOURCE: Hemispherx Biopharma, Inc.

[Geheimnisvoller]

http://quotes.nasdaq.com/asp/summaryquote.asp?symbol=HEB%60&…

Hier der link

Eigenartig, die Aktie wird im Moment nicht gehandelt???
Wer hat eine Erklärung?

[Geheimnisvoller]

Doch, jetzt wird gehandelt. Schon um 8% gestiegen.

[greyhound_cc]

SHORTINTEREST WEITER GESTIEGEN ZUM 13.ten JUNI!

DAS WIRD BALD EIN REBOUND GEBEN....

[schwarzu]

wo sind denn die Optimisten geblieben?
ad #10:
es scheint wieder sehr viel mehr verkauft als gekauft zu werden!
Die News können nicht überzeugen! Weiss da jemand mehr wie wir und immerhin sind es über eine Million Stück die gestern gehandelt wurden und heute dürften noch mehr gehandelt werden. Wer verkauft denn da unter 2 $? Wo führt das noch hin?
News gibts keine zur Zeit (zumindest keine die überzeugend wären) und diskutiert wird auch nicht über diese Aktie.
Langsam aber sicher hangelt sie sich nach unten! Unter 2 $ wollte ich verkaufen und werde vermutlich heute noch abwarten und dann spätestens am Montag verkaufen! Ohne Nachrichten, ohne Infos ist das reine Zeitverschwendung und Geldvernichtung!

Gruß schwarzu

[Jonnyboy2000]

@schwarzu

ich kann dir leider nur zustimmen mit deinen Äusserungen über diese Aktie.
Ich schaue mir das jetzt mittlerweile seit 2 Monaten an, habe mir auch über die früher stattgefundenen Diskussionen in diversen Threads ein Bild gemacht, zusätzlich habe ich versucht mit HEB selbst ins Gespräch zu kommen und bin letztendlich zu dem Schluß gekommen, daß hier zwar immer noch ein paar Pusher rumhüpfen aber alles in allem bekommen die nicht wirklich was auf die Reihe. Die Informationspolitik scheint bei HEB Standard zu sein. Es werden immer mal wieder ein paar Nachrichten veröffentlicht, die den Kurs mal wieder etwas anheizen, aber dingfeste Fakten, daß da tatsächlich mal Geldverdienen in Aussicht wäre, sehe ich leider nicht.
Das einzige was mich im Moment an diesem hundsmiserablen Kurs noch ein wenig positiv stimmt, ist der Fakt, daß der CEO Carter diesen Monat sehr viel mehr Aktien auf den Markt schmeisen muß, um an sein gewohntes monatliches Sümmchen zu kommen.
Das letzte ist allerdings nur noch reine Schadenfreude und Sarkasmus als Heilmittel gegen meine Entäuschung. Ich bin nur froh, daß ich mir von dieser Aktie keinen größeren Bestand angeschafft habe und von daher die blöden Dinger liegen lassen kann.

Gruß Jonny

[greyhound_cc]

tztz...geduld sollte man haben...

oder einfach verkaufen....

[schwarzu]

@greyhound..

Geduld um auf was zu warten? Ein Verlust von ca.40% ist schon einiges! In der Vergangenheit hatte ich mehrfach gehalten und was ist passiert? Viele Werte sind zu Pennystocks mutiert, oder ex. nicht mehr. Gibt es Deiner Meinung nach fundamentale Gründe zum Halten?
"..oder einfach verkaufen": Haben wir diesen Diskussionsthread um den Mund zu halten und einfach zu verkaufen. Was besseres fällt Dir nicht ein!? Besser wäre es fundamentale Gründe zu nennen, so Du welche kennst (und das gestiegene Short interest hat gar nichts zu bedeuten; die wissen das sie es mit einem kleinem Biotech Wert zu tun haben und solange keine positiven News kommen, wird der Wert fleissig weiter und erfolgreich geshortet).

Gruß,
Schwarzu

[Geheimnisvoller]

Heute wieder um 5% gestiegen. Der Trend ist eingeleitet.
Deine 40% minus werden sich noch in Plus umwandeln.

[schwarzu]

Hi Geheimnisvoller,

eines ist in den letzten 2 Wochen zu erkennen gewesen. Die Aktie steigt am Anfang des Börsentages um dann gegen Ende wieder abzugeben. Irgendwie noch nicht so richtig überzeugend.
Leider gibt es wenige Infos und News, so das eine Einschätzung sehr schwierig ist. Wie es mit der Zulassung ihres Kernprodukts AMPLIGEN durch die FDA aussieht ist auch nicht klar. Das kann sich erfahrungsgemäss lange hinziehen.
Ich habe mal eine zeitlang den livechart von hemisph. auf ragingquote beobachtet. Interessant war das der Kurs vehement hoch ging um dann mit kleinen Orders (ca.300 Stück) wieder gedrückt zu werden.


Gruß Schwarzu

[Jonnyboy2000]

Hi,

wie ich vorausgesagt hatte.
Diesen Monat mußte der Carter schon 14000 Teile verkaufen, um auf sein monatliches Quantum zu kommen!
Wenn die Firma weiterhin keine vernünftigen Fakten veröffentlichen kann, werden es nächsten Monat wieder mehr Teile sein.

@Geheimnisvoller

Siehst du jetzt deutlicher wo dein Trend tatsächlich langgeht?

Gruß Jonny

[Geheimnisvoller]

#27 von Jonnyboy2000

Steigt oder fällt die Aktie?
Steigend geht der Trend!

[Jonnyboy2000]

@Geheimnisvoller

An Frankfurter Börse:

52 W Perf. = -36,67%
4 W Perf. = -24,90%

An Amex (USD):

52 W Perf. = -28,06%
4 W Perf. = -31,27%

... und ansonsten solltest du dir vielleicht mal ein 3- Jahreschart oder noch länger ansehen, um etwas mehr Klarsicht zu bekommen. Wenn wir Glück haben, wird diese Aktie auch mal wieder zu den ursprünglichen Kursen zurückkommen. Aber eben nur mit Glück!!!

Noch eins zum Nachdenken: Ich habe wirklich nichts gegen vorübergehend fallende Kurse, das ist der Lauf der Dinge an der Börse und bei Unternehmen die etwas auf die Beine stellen können, wird sich so etwas auch wieder regulieren.
Aber das was du hier so postest, kann ich nur noch dummes rumgepushe nennen.

Ohne Gruß Jonny

[Masse]

@ Schwarzu

Ich bin schon über 5 Jahre in Hemispherx investiert, und warte also schon 5 Jahre auf die Zulassung von Ampligen. Ob sie jemals kommen wird - ich weiß es nicht. Wenn es doch noch zur Zulassung kommt, sind Kurse über 25 $ realistisch --> das ist die Chance.

Mit den Short Seller gab es schon immer Probleme. Der "Kollege" Asensio führt da seinen Privatkrieg mit Hemispherx-Chef William Carter. Ich habe immer die kleine Hoffnung, das sich die Short Seller irgendwann mächtig die Hände verbrennen.

Ich weiß nicht, ob ich Dir geholfen habe, ich bin selber nicht schlüssig - ich hänge schon zu lange in Hemispherx und bin sicher nicht mehr objektiv genug. Ich wünsche Dir viel Glück.

Schau doch mal nach China, da steigen seit einem Jahr die Werte wirklich (SINA, SOHU, NETEASE, XING) in den Himmel...

Gruß Masse

[schwarzu]

@ Masse

danke für Dein Statement! Die Frage ist zur Zeit ob die 2-3$ Preis für Hemispherix bereits zu teuer sind, solange Ampligen noch keine Zulassung hat. Assensio ist mir ein Begriff. Der wühlt überall dort rum wo mit kurzfristigen positiven Meldungen nicht zu rechnen ist und verdient mit der Negativ Stimmung der Anleger. Dies geht natürlich nur bei den kleineren Werten (bevorzugt kleinere Pharmatitel), oder in einem negativen Börsenumfeld (was wir zur Zeit nicht haben).
Ich bin bereits in China investiert und habe da auch Gewinne realisiseren können, auch wenn mir die diversen SINA, NETEASE etc. leider durch die Lappen gegangen sind.

Grüsse,
Schwarzu

[Masse]

@ Schwarzu

Ich habe mir durch eine Empfehlung von VMR Hemisperx ins Depot gelegt. VMR war, durch ein Research bei Hemisperx, voll überzeugt.

Im Februar 2001 erschien dann folgendes Interview mit VMR:
Im Gespräch mit Philip Steinhauer äußert sich Matthias Girnth, Executive Director des Bereiches Corporate Finance, zu aktuellen Entwicklungen bei VMR.

„GSC Research: Ein sicherlich unrühmliches Ereignis Ihres Beteiligungsgeschäfts war die Beteiligung an dem inzwischen zum Penny-Stock verkommenen US-Biotech-Wert Hemisperx. Besteht dieses Engagement noch? Haben sich nicht im Rückblick die Aussagen des Shortsellers Manuel Asensio als richtig erwiesen?

Matthias Girnth: Penny-Stock kann man bei 5 Dollar nicht sagen. Im Übrigen hat Manuel Asensio den Prozess gegen Hemispherx verloren und eine ziemliche Strafe von der NASD (Nasdaq-Betreiber) bekommen.

GSC Research: Der Kurs von Hemispherx ist aber auch als "out of business" zu bezeichnen. Zumindest hat es dort trotz Biotech-Euphorie im letzten Jahr keine berauschend positive Entwicklung gegeben.

Matthias Girnth: Nein, der Kurs hat sich nach unserer Empfehlung erst von 6 Dollar auf fast 20 Dollar entwickelt, jetzt steht er bei 5 Dollar. Wir haben uns getrennt, da die Milestones, die das Management gegenüber uns - und wir haben sehr intensives Research betrieben - vorgegeben hat, immer nach hinten verschoben wurden. Das hat bei uns zu der Konsequenz geführt, dass wir keine Stücke mehr haben. Wir haben uns von der Beteiligung mit Gewinn getrennt.“

VMR hat sich von Hemisperx vollständig getrennt, weil die Zeitpläne nie eingehalten wurden. Es scheint, das Hemisperx nun „kurz“ vor der Zulassung steht! Wenn es nicht zu der Zulassung kommt, wird der Kurs weiter fallen. Aber wenn es zur Zulassung kommt, dann sind nach der Studie von VMR Kurziele von 50 $ drin (telefonische Aussage von VMR –Mitarbeiter im Jahr 1999). Für mich persönlich macht es keinen Sinn die Verluste mit Hemisperx zu realisieren, da ich schon zu lange drin hänge. Die Nachrichten in der letzten Zeit zeigen, das ein „Ende“ in Sicht ist. Ich rechne aber nicht wirklich in der nächsten Zeit mit einem Durchbruch – und übe mich in Sachen Hemisperx weiter in Geduld!

Gruß Masse
Der Link zum vollständigen Interview:
http://www.vmr.de/index.php?VMR_Session=03caba73e92cfa9d4a87…

[greyhound_cc]

Hemispherx Completes $5,500,000 Private Placement; Second $5.5 Million Transaction in Four Months to Accelerate Market Development and Additional Commercial Approvals

PHILADELPHIA, Jul 11, 2003 (BUSINESS WIRE) -- Hemispherx Biopharma, Inc. (AMEX:HEB) announced today that it completed an approximately $5.5 million transaction through an offering of senior convertible debentures due July 31, 2005. The debentures may be convertible into Hemispherx common stock at a price equal to the average closing price of the shares over the last seven days. The closing price of the stock on July 10 was $2.21. The Company also grants warrants to purchase an amount of shares of common stock equal to 20% of the shares issuable upon conversion of the debentures. The warrants are exercisable at a 15% premium over the conversion price.

The funds, with the diligent help of Cardinal Securities, LLC acting as placement agent, were raised through Ramius Capital Group (www.ramius.com) and Angelo Gordon and Co. (www.angelogordon.com). The Company has completed an identical transaction with these two institutional investors in March of this year.

The net proceeds of this transaction will go toward the further development and finalization of its clinical program with the experimental agent Ampligen(R) and the commercial program of Alferon(R), approved by the FDA for genital HPV and currently the only FDA approved natural interferon therapy. The funds also give momentum to meet the Company`s year 2003 targets, including the commercial launch of Alferon N Injection(R) for genital HPV, securing strategic partners for sales and distribution of the Alferon(R) program worldwide, securing further licensing arrangements for the Ampligen(R) program in Europe, completion of the Phase III clinical trial with the experimental compound Ampligen(R) in Chronic Fatigue Syndrome (CFS) by year`s end, finalization of the regulatory strategy for a NDA filing, acceleration of patient enrollment in the ongoing Phase IIb clinical studies for HIV, as well as further development of the Company`s Bioterror National Security program and finalization of the regulatory filings and planning of clinical trials for SARS.



Genehmigung bald?!

[greyhound_cc]

ÄÄÄHHMM...NEWS!

Hemispherx Reports New HIV Treatment Data on Ampligen at the 2nd IAS Conference on HIV Pathogenesis and Treatment

PHILADELPHIA, Jul 15, 2003 (BUSINESS WIRE) -- Initial Therapeutic Data on Immune Response Now Confirmed over Significantly Longer Observation Period

Hemispherx Biopharma, Inc. (AMEX:HEB) announced today that at the 2nd IAS Conference on HIV Pathogenesis and Treatment in Paris, France, most recent data of its Phase IIb clinical trial, AMP 720, was reported. Using Strategic Treatment Interruption (STI), patients` antiviral HAART regimens are interrupted and Ampligen(R) is substituted as mono-immunotherapy. Ampligen(R) is an experimental immunotherapeutic designed to display both antiviral and immune enhancing characteristics.

About the Conference

The 2nd IAS Conference on HIV Pathogenesis and Treatment (www.ias2003.org) is held in Paris, France, July 13-17. The International AIDS Society (IAS) is the world`s professional society representing clinicians and public health experts engaged in HIV/AIDS research, prevention, care and treatment. The IAS has more than 10,000 members representing more than 130 countries, backed by affiliated regional and national HIV/AIDS societies. The Conference is organized in scientific collaboration with National Institutes of Health (NIH) and Center of Disease Control and Prevention (CDC).

Toxicity of HAART

Prolonged use of Highly Active Antiretroviral Therapy (HAART) has been associated with long-term, potentially fatal, toxicities. The clinical study AMP 720 is designed to address these issues by evaluating the administration of the Company`s lead experimental agent, Ampligen(R), a double stranded RNA drug acting potentially both as an immunomodulator and antiviral.

Clinical Results

Patients, who have completed at least 9 months of Ampligen(R) therapy, were able to stay off HAART for a total STI duration with a mean time of 29.0 weeks (and continuing), whereas the control group, which was also taken off HAART, but not given Ampligen(R), had earlier HIV rebound with a mean duration of 18.7 weeks (p = 0.05). Thus, on average, Ampligen(R) therapy spared the patients excessive exposure to HAART, with its inherent toxicities, for more than 11 weeks.

The HAART regimen combines multiple drugs that directly attack the HIV virus, often leading to virus mutation and drug resistance. In contrast, the Ampligen(R) therapy has been generally well tolerated in the HIV population with no evidence to date of any increase in toxicities commonly seen with the existing HAART regimens.

These present results substantially enlarge the data, presented earlier at different international conferences, including the DART Conference in late 2002, by providing clinical observation over a much longer treatment period.

About Hemispherx

Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based chronic disorders. Its flagship products include Alferon(R) and the experimental immunotherapeutics/antivirals Ampligen(R) and Oragens(R). These novel proteins, approved for a category of STD infection, and experimental nucleic acids are being developed for globally important chronic viral diseases and disorders of the immune system including HPV, HIV, CFS and Hepatitis. Its platform technology includes large and small agent components for potential treatment of various chronic viral infections. Hemispherx has approximately 400 patents comprising its core intellectual property estate, a fully commercialized product (Alferon N) and GMP certified manufacturing facilities for its novel pharma products. For more information please visit www.hemispherx.net

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company`s filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the company (including Ampligen(R) and Oragens(TM)) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company`s judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon(R) do not imply that the product will ever be specifically approved commercially for these other treatment indications including SARS. The Alferon(R) asset for overseas sales for a category of STD is currently being acquired by the Company as part of a multi-step purchase contract of inventory, intellectual property, commercial licenses and GMP approved facilities, which house the biological operations.

[greyhound_cc]

Hemispherx Biopharma is a biopharmaceutical company engaged in the clinical
development, manufacture, marketing and distribution of drug entities based on
natural immune system enhancing technologies. Its lead compounds are ALFERON
N Injection®, a natural form of human leukocyte derived Interferon currently approved
by the FDA for a category of sexually transmitted diseases (STD’s) and AMPLIGEN®
a nucleic acid, which is in Phase 2b clinical studies for HIV/AIDS and a Phase 3
clinical study for Chronic Fatigue Syndrome (CFS). Alferon and the experimental
agent Ampligen offers the Company a unique experimental platform of immune
based therapies that shows substantial potential to benefit the scientific community
regarding HIV/AIDS, CFS, hepatitis, bioterror and various STD’s.
• The Company has a R&D investment of over $ 450 Million and has established a
strong foundation of laboratory, pre-clinical and clinical data with respect to the
development of its products.
• Intellectual Property: with over 400 U.S. and international patents, regarding
ALFERON N Injection®, Ampligen® and Oragen® (small molecular size RNA drugs,
taken orally, in preclinical status), Hemispherx holds one of the largest patent
portfolios in the global biopharmaceutical sector.
• The Company has a FDA approved GMP manufacturing facility.
• The Company has a FDA Commercial Approval for Alferon for the treatment of
condylomata HPV. There are approx. 1 Million new cases of HPV in the U.S. yearly.
• The Company has a treatment IND status for the treatment of CFS, there are approx.
500,000 Americans suffering from CFS, according to the CDC.
Technology Pipeline
AMPLIGEN
PROGRAM
ALFERON
PROGRAM
BIOTERROR
PROGRAM
CFS
Phase 3
HIV Salvage
Phase 2b
HIV S.T.I.
Phase 2b
STD
Product Launch
HIV / HEP-C
Phase 2/3 Prep.
MS
Phase 2 Prep
Government
Funded Trials
SMALLPOX
WESTNILE
SARS
WOMEN’S HEALTH
SPECIALTY
MARKETS
NATIONAL
SECURITY
CHRONIC DISEASES
TREATMENTS

[diddelmax]

[Alex00]

No dann!!
Schaun mer mal. ;-
Positiv ischt doch in lätzta Zait gnug gschrieba worda. Waretn mer´s ab. Ergend ebbes werd schoa passiere.
Short interschd sind gschdiege, liegä abbr no em Rahme, schteiged des Grobzaig emmer no, dann kenne mer Kurse om dr 1,80 ouglotze (em momend um dr 4,8 also sche rouhig blaibe ond Boi baumle la).
Zom Tradding oifach guat. Genegend Speelraum zom zocke.
Uff dr Jahuuh Said send gnegend Leid, die absoluad bullish send (Dr RSI dräht ond dr MACD zuggt au in dr guate Breich)
Wia g´said schau´n mer mal.
alex

[HansH]

Quelle:www.yahoo.com

Hemispherx Reports Ampligen Prevents Destruction of
Nerve Cells and Increases Survival Rates in Flavivirus Infection
Tuesday July 29, 8:33 am ET
Independent Study shows Ampligen(R) demonstrates Broad-Based Potential in Virus Classes associated with Bioterror and West Nile Virus

PHILADELPHIA--(BUSINESS WIRE)--July 29, 2003-- Hemispherx Biopharma, Inc. (AMEX: HEB - News) reported today the results of a new animal study, indicating the specific promise of Ampligen®, the Company`s flagship investigational therapeutic, in experimental animal flavivirus encephalitis. The independent study was conducted by the Antiviral Research Group led by Professor Johan Neyts of the Rega Institute, KUL, Leuven, Belgium. No contracts, grants, financial compensation or other means of indirect support were provided to the research team or to the academic institution.

About the Study

Flaviviruses represent a broad group of potentially devastating viruses, including West Nile Virus, Equine Encephalitis virus, Dengue Fever virus and Japanese Encephalitis in children, where 33% of patients die acutely. The animal study evaluated the effect of clinical grade interferon and Ampligen®, an experimental immunotherapeutic, on encephalitis virus induced morbidity and mortality as well as the mean day to development of paralysis. Untreated animals with flavivirus (Modoc virus was used) showed generalized paralysis, tremor, and flaccid paralysis of hind legs before death.

"SCID" mice were used in the study, which manifest severe combined immunodeficiency disease, which is a profound genetic deficiency in their immune systems making animals unusually susceptible to morbidity and death from viral infections.

The Phase II investigational agent Ampligen® reduced virus concentrations in the brain dramatically by 99%, as well as the blood stream (serum) by more than 99% and was far superior to treatments with the clinical grade products, recombinant interferon (IFN) or pegalated IFN (a more potent newer version of IFN).

Pre or post treatment with Ampligen® significantly decreased both mean day of paralysis and the mean day of death. Ampligen® alone was also more effective with these efficacy parameters than the combination of clinical grade recombinant interferon alpha 2-b with ribavirin (Ribavirin alone had a very small protective effect). Ampligen® superiority was demonstrated by 35 days versus the interferon combination 20 days vs. untreated 16 days as average day to death in the animals succumbing to the infection. Only clinical testing under well controlled conditions can determine efficacy and safety on entity including Ampligen® in Flavivirus infections.

[HansH]

Quelle;http://biz.yahoo.com/bw/030804/45302_1.html
Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Receives New Patents for Oral Dosed Broad-Spectrum Immune Activators
Monday August 4, 8:34 am ET
Company Prepares Applications to Bioterror and Emerging Infectious Diseases Granting Programs

PHILADELPHIA--(BUSINESS WIRE)--Aug. 4, 2003-- Hemispherx Biopharma, Inc. (AMEX: HEB - News), a leading company in the experimental-stage development of immune based therapies primarily addressing the diseases of Chronic Fatigue Syndrome, HIV/AIDS and HPV, announced today the receipt of major new patents in Europe on a set of orally active low molecular weight RNA compounds, trade marked "ORAGENS®", which are designed to function within a broad spectrum of antiviral and immunological activities.

International Research Consortium: Government and Academic Researchers

Because of the unusual breadth and scope of the application, nearly 14 years were required for successful prosecution and issuance of the patents. During the intervening years, important collaborations were created with U.S. and European Universities, especially those in Germany, as well as the National Institutes of Health (NIH). The results of these collaborations, published and/or pending applications in peer review journals, establish the therapeutic promise of these new experimental drug entities in various chronic diseases associated with immune dysfunction and chronic viral replication or viral "footprints".

Possible Application to Bioterror, National Defense Program

Bioterror attacks may require initial strengthening of first line of immune defense while the attacking agent is being identified. Oragens® may serve such a role because of their unique mechanism of action on the dormant human immune system.

Oral Applicability

The intent of the patents is to offer a relative ease and convenience of oral dosing in chronic diseases where currently injection or infusion is the common method of drug introduction. Typically, oral applications dramatically broaden the use of drugs and increase patient compliance in both clinical trial and post approval use as compared with intravenous infusion or intramuscular injection.

Scope of Patents

The patents designated "Phosphorothioate/Phosphodiester Oligoadenylates and Antiviral Uses thereof" are being issued in 8 countries: Germany, France, United Kingdom, Spain, Switzerland, Ireland, Belgium and Luxembourg. Hemispherx`s European subsidiary, Hemispherx Biopharma Europe, announced last year a significant licensing and equity placement surrounding one of its lead high molecular weight RNA compounds, termed Ampligen®, which is in Phase 3 clinical trials and is a parentally injected product. Hemispherx is evaluating manufacturing worldwide to facilitate the potential scaling up of production of specific Oragens®.

[HansH]

Das Volumen an der AMEX zieht wieder an!

Gruß
HansH